Comment diagnostiquer l'exposition au MPP+ ?

Des tests biologiques et des évaluations neurologiques sont utilisés pour diagnostiquer l'exposition.

Quels examens sont recommandés pour le MPP+ ?

L'IRM et l'électromyographie peuvent aider à évaluer les dommages neurologiques.

Quels symptômes indiquent une intoxication au MPP+ ?

Des tremblements, rigidité et bradykinésie peuvent indiquer une intoxication au MPP+.

Le MPP+ peut-il être détecté dans le sang ?

Oui, des analyses sanguines peuvent détecter la présence de MPP+.

Quels tests neurologiques sont utiles pour le MPP+ ?

Des tests de coordination et de réflexes peuvent évaluer l'impact neurologique du MPP+.

Quels sont les symptômes principaux du MPP+ ?

Les symptômes incluent tremblements, rigidité musculaire et troubles de la marche.

Le MPP+ cause-t-il des troubles cognitifs ?

Oui, l'exposition au MPP+ peut entraîner des troubles cognitifs et de la mémoire.

Y a-t-il des symptômes non moteurs liés au MPP+ ?

Oui, des symptômes comme la dépression et l'anxiété peuvent survenir.

Comment le MPP+ affecte-t-il le système nerveux ?

Le MPP+ endommage les neurones dopaminergiques, entraînant des symptômes parkinsoniens.

Le MPP+ provoque-t-il des douleurs ?

Oui, des douleurs musculaires et articulaires peuvent être présentes chez les patients.

Comment prévenir l'exposition au MPP+ ?

Éviter les environnements contaminés et utiliser des équipements de protection.

Y a-t-il des vaccins contre le MPP+ ?

Actuellement, il n'existe pas de vaccin spécifique contre le MPP+.

Les changements de mode de vie aident-ils à prévenir le MPP+ ?

Oui, un mode de vie sain peut réduire le risque de maladies neurodégénératives.

L'éducation sur le MPP+ est-elle importante ?

Oui, l'éducation sur les risques et les symptômes est essentielle pour la prévention.

Les contrôles réguliers sont-ils recommandés ?

Oui, des contrôles réguliers peuvent aider à détecter précocement les symptômes.

Quels traitements sont efficaces contre le MPP+ ?

Les traitements incluent des médicaments dopaminergiques et des thérapies physiques.

La réhabilitation est-elle utile pour les patients exposés au MPP+ ?

Oui, la réhabilitation aide à améliorer la mobilité et la qualité de vie des patients.

Peut-on utiliser des antioxydants pour traiter le MPP+ ?

Des antioxydants peuvent être envisagés pour réduire le stress oxydatif lié au MPP+.

Les thérapies complémentaires sont-elles bénéfiques ?

Certaines thérapies complémentaires, comme l'acupuncture, peuvent soulager les symptômes.

Le traitement précoce du MPP+ est-il crucial ?

Oui, un traitement précoce peut ralentir la progression des symptômes parkinsoniens.

Quelles complications peuvent survenir avec le MPP+ ?

Des complications incluent des troubles moteurs sévères et des problèmes cognitifs.

Le MPP+ peut-il entraîner des chutes ?

Oui, les troubles de la marche augmentent le risque de chutes chez les patients.

Y a-t-il un risque accru de dépression avec le MPP+ ?

Oui, les patients exposés au MPP+ présentent un risque accru de dépression.

Le MPP+ peut-il affecter la qualité de vie ?

Oui, les symptômes parkinsoniens peuvent significativement réduire la qualité de vie.

Des complications cardiovasculaires sont-elles possibles ?

Oui, des études suggèrent un lien entre MPP+ et complications cardiovasculaires.

Quels sont les principaux facteurs de risque du MPP+ ?

L'exposition à des pesticides et à des produits chimiques industriels augmente le risque.

L'âge est-il un facteur de risque pour le MPP+ ?

Oui, le risque d'effets néfastes du MPP+ augmente avec l'âge.

Les antécédents familiaux influencent-ils le risque ?

Oui, des antécédents familiaux de maladies neurodégénératives augmentent le risque.

Le sexe joue-t-il un rôle dans le risque de MPP+ ?

Oui, des études montrent que les hommes sont plus à risque que les femmes.

Le mode de vie influence-t-il le risque de MPP+ ?

Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque.

1-Méthyl-4-phényl-pyridinium - Informations médicales vérifiées

Pleiotropic effects of clopidogrel.

09 2022

DOI: 10.1007/s11302-022-09876-0 PMID: 35678974

Clopidogrel is a widely prescribed prodrug with anti-thrombotic activity through irreversible inhibition of the P2Y...

Blood Platelets Clopidogrel Humans Platelet Aggregation Inhibitors Purinergic P2Y Receptor Antagonists +3 autres

Ticagrelor Aspirin vs Clopidogrel Aspirin in

31 01 2023

DOI: 10.1212/WNL.0000000000201454 PMID: 36535779

Genotype data of the Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) trial showed that efficacy of clopidogrel aspirin depended on... Data were obtained from Ticagrelor or Clopidogrel with Aspirin in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial. Low-risk and high-risk profiles were defined by... A total of 6,412... This post hoc analysis of CHANCE-2 trial showed that... This study provides Class II evidence that... URL: www.... gov. Unique identifier: NCT04078737....

Humans Clopidogrel Aspirin Ticagrelor Ischemic Attack, Transient +8 autres

Ticagrelor-Aspirin Versus Clopidogrel-Aspirin Among

11 2022

DOI: 10.7326/M22-1667 PMID: 36315949

Evidence on the risk-benefit ratio of dual antiplatelet therapies among patients with stroke and impaired renal function is limited and inconsistent.... To investigate the effect of renal function on the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin treatment.... Post hoc analysis of a multicenter, randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT04078737).... 202 centers in China.... Ticagrelor-aspirin and clopidogrel-aspirin.... Renal function was evaluated by estimated glomerular filtration rate (eGFR) levels. The primary efficacy and safety outcomes were recurrent stroke and severe or moderate bleeding within 90 days, respe... Among 6378 patients, 4050 (63.5%) had normal (eGFR ≥90 mL/min/1.73 m... Renal function was only evaluated by using eGFR, and the proportion of patients with severely decreased renal function was low.... Patients with normal, rather than impaired, renal function received greater benefit from ticagrelor-aspirin versus clopidogrel-aspirin.... Ministry of Science and Technology of the People's Republic of China....

Humans Aspirin Cerebral Infarction Clopidogrel Cytochrome P-450 CYP2C19 +8 autres

Differential inhibition of platelet function by cilostazol in combination with clopidogrel.

Dec 2023

DOI: 10.1007/s00228-023-03553-w PMID: 37740121

To assess the antiplatelet effect of cilostazol clinically, we compared the effects of cilostazol in combination with clopidogrel on various platelet function tests.... We recruited patients with ischemic stroke at high risk of recurrence who were treated with clopidogrel alone within 180 days after stroke onset. Subjects underwent baseline platelet function tests, a... Thirty-four patients were enrolled, but 4 patients were excluded for various reasons. In total, 30 subjects (13 in DAPT and 17 in SAPT group) were analyzed. Adenosine diphosphate- and collagen-induced... The inhibitory effects of adjunctive cilostazol added to clopidogrel on platelet function differed by type of platelet function test. VerifyNow % inhibition and PRI were more inhibited than the other ... CSPS.com substudy in TWMU (UMIN000026672), registered on April 1, 2017. This study was performed as a substudy of CSPS.com (UMIN000012180, registered on October 31, 2013) and was retrospectively regis...

Humans Clopidogrel Cilostazol Platelet Aggregation Inhibitors Ticlopidine +5 autres

High On-Treatment Platelet Reactivity: Aspirin versus Clopidogrel.

2023

DOI: 10.1159/000527816 PMID: 36463859

Antithrombotic regimen in patients on oral anticoagulation (OAC) post-percutaneous coronary intervention (PCI) is challenging. At least, one antiplatelet agent in combination with OAC is recommended a... In this retrospective single-center database analysis, we investigated platelet reactivity by light transmission aggregometry in patients under different antiplatelet regimes. Results were presented a... 755 patients were enrolled. 677 were on ASA, 521 were on clopidogrel, and 198 had OAC. Overall mean age was 73 ± 13.4 years, and 458 (60.7%) were male. HTPR to ASA occurred in 94/677 patients (13.9%),... Impaired pharmacodynamic response to clopidogrel was more frequent as HTPR to ASA. Hence, ASA should be tested in combination with OAC post-PCI....

Humans Male Middle Aged Aged Aged, 80 and over +9 autres

Response to clopidogrel in patients undergoing lower extremity revascularization.

Dec 2023

DOI: 10.1177/17085381221103417 PMID: 35590464

Clopidogrel is effective at decreasing cardiovascular events in patients with peripheral artery disease (PAD); however, its effect on limb outcomes are less known. This study investigated the variabil... Three hundred subjects were enrolled in the Platelet Activity and Cardiovascular Events (PACE) study prior to lower extremity revascularization, of whom 104 were on clopidogrel. Light transmission pla... Overall, the median age was 70 (63, 76) and 35.6% were female. Twenty-nine (27.9%) patients experienced MALE during their follow-up. Median aggregation to ADP 2... Among patients undergoing lower extremity revascularization on clopidogrel, higher baseline percent aggregation is associated with increased risk for major adverse limb events....

Humans Female Aged Male Clopidogrel +4 autres

Hypereosinophilic syndrome presenting as eosinophilic gastroenteritis exacerbated by clopidogrel bisulphate.

01 Dec 2023

DOI: 10.2478/rjim-2023-0022 PMID: 37671558

Clopidogrel is a widely prescribed prodrug with antithrombotic activity that functions by irreversibly inhibiting the P2Y12 receptors on platelets; nevertheless, drug-induced eosinophilia from this dr...

Male Humans Aged, 80 and over Clopidogrel Hypereosinophilic Syndrome +3 autres

Atorvastatin Effect on Clopidogrel Efficacy in Patients with Peripheral Artery Disease.

Sep 2023

DOI: 10.1016/j.avsg.2023.05.023 PMID: 37257642

Both clopidogrel and atorvastatin metabolism are rooted in hepatic cytochrome p450 activation. There are published reports of atorvastatin interfering with clopidogrel metabolism by inhibiting the act... All patients undergoing revascularization between December 2020 and August 2022 were prospectively evaluated. Patients on clopidogrel and atorvastatin were compared to those on clopidogrel alone. Seri... Over the study period, a total of 182 patients were enrolled. Of this cohort 72 patients met study criteria. 87 samples from the 72 patients were analyzed. 31 (43.05%) patients were on clopidogrel alo... Patients on clopidogrel and atorvastatin showed significantly less platelet inhibition compared to those on clopidogrel alone, supporting the concept that atorvastatin may interfere with the therapeut...

Humans Clopidogrel Atorvastatin Platelet Aggregation Inhibitors Ticlopidine +7 autres

Comparison of ticagrelor and clopidogrel on platelet function and prognosis in unstable angina.

Dec 2022

DOI: 10.1007/s00228-022-03401-3 PMID: 36245047

This study aims to compare the effects of ticagrelor and clopidogrel on platelet function, cardiovascular prognosis, and bleeding in patients with unstable angina pectoris.... Patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI) were enrolled (January 2018-December 2019). In total, 212 patients were treated with ticagrelor (90 mg twice ... The PAR was significantly slower with ticagrelor (P < 0.001). hs-TnT, NT-proBNP, CRP, and h-FABP increased after compared with before PCI in both groups (P < 0.05). hs-TnT (P < 0.001) and h-FABP (P < ... Ticagrelor was more effective in suppressing the PAR than clopidogrel and reduced PCI-induced myocardial injury in patients with unstable angina pectoris. However, it increased in-hospital and 12-mont...

Humans Ticagrelor Clopidogrel Fatty Acid Binding Protein 3 Percutaneous Coronary Intervention +5 autres

The DNAm levels of CREB5 (cg11301281) were associated with clopidogrel resistance.

Oct 2022

DOI: 10.1002/jcla.24690 PMID: 36087301

Clopidogrel resistance (CR) is mostly caused by interindividual variability of the platelet inhibition of clopidogrel, which may induce cardiovascular events. The aim of this research was to evaluate ... 72 patients(36 CR and 36 non-CR) who underwent ACS were included in this study. The VerifyNow P2Y12 assay was selected to evaluate residual platelet reactivity, and bisulfite pyrosequencing methods wa... Subunit analysis indicated that for patients whose HbA1c levels were ≥6.5% or whose GLU levels were ≥7 mmol/L, lower methylation of cg01534253 indicated a poorer clopidogrel response. In addition, CRE... Our findings were likely to provide fresh understanding for the new mechanism of platelet inhibition failure and promote individualized antiplatelet therapy....

Acute Coronary Syndrome Albumins Blood Platelets Clopidogrel Cyclic AMP Response Element-Binding Protein A +6 autres

1-Méthyl-4-phényl-pyridinium : Questions médicales fréquentes

Termes MeSH sélectionnés :

Questions fréquentes et termes MeSH associés

Diagnostic 5

Symptômes 5

Prévention 5

Traitements 5

Complications 5

Facteurs de risque 5

Contenu validé par Dr Olivier Menir

Auteurs principaux

Sources (503 au total)